Market Overview:
The global viral vector development service market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for gene therapy and rising prevalence of chronic diseases. In addition, the growing number of biotechnology companies and research institutes is also contributing to the growth of this market. On the basis of type, retroviral vectors are expected to account for a major share in the global viral vector development service market during the forecast period. This can be attributed to their ability to transfer genetic material into target cells and their high efficiency in gene delivery. On the other hand, adeno-associated viral vectors are projected to witness highest growth rate during 2018-2030 owing their advantages such as low immunogenicity and lack of pathogenicity.
Product Definition:
A viral vector development service is a company or organization that provides custom-made vectors for the delivery of genes or other therapeutic molecules into cells. The purpose of using a viral vector is to increase the efficiency with which the desired molecules are delivered into target cells, thereby improving the effectiveness of gene therapy or other cellular therapies.
Retroviral Vectors:
Retroviral vectors are used for the construction of recombinant viruses. The most commonly used viral vector is the adenovirus which has been extensively studied and found to be a good candidate for many gene therapies. Adenoviruses are also known as serotype 5 because they have 50% homology with human immunoglobulin G (HIGG) binding protein, which allows them to bind and infect human cells.
Lentiviral Vectors:
Lentiviral vectors are a class of viral vectors that contain the gene for the production of an enzyme called “lentivectorial”. The lentivirus genome is packaged into a protein complex known as the lysosome which enables it to traffic through cell membranes and infect host cells. This virus can be used in gene therapy, vaccinology, and research applications among others.
Application Insights:
The pharmaceutical manufacturers segment dominated the market in 2017 and is expected to maintain its dominance over the forecast period. This can be attributed to factors such as extensive usage of adeno-associated viral vectors for gene therapy, expression of proteins, and delivery of genes into cells in research studies. Furthermore, increasing R&D activities pertaining to development of novel adenoviral vector systems for cancer treatment is also likely to contribute towards revenue generation.
Adoption of AAV vectors by biotechnology companies for intracellular protein delivery has increased significantly over the past few years owing to their ability not only deliver genes but also act as a platform for various other applications including cell line engineering and genetic modification.
Regional Analysis:
North America dominated the market in terms of revenue share in 2017. The growth can be attributed to the presence of a large number of players, increasing investment by these companies for research and development activities, and high adoption rate for advanced technologies across several sectors including agriculture, food & beverage industry, animal health & veterinary medicine. Moreover Viral Vectors are widely used across industries such as biotechnology and pharmaceuticals for production of therapeutic proteins or vaccines against various diseases.
The Asia Pacific is expected to witness lucrative growth over the forecast period owing to factors such as growing economy with improving healthcare infrastructure leading towards better treatment outcomes along with rising awareness about emerging infectious diseases among people thereby driving demand for viral vector development services in this region. Furthermore government initiatives coupled with increased spending on R&D activities are anticipated to fuel regional market growth during the forecast period (2018-2030).
Growth Factors:
- Increasing demand for gene therapy and regenerative medicine
- Rising prevalence of chronic diseases
- Technological advancements in viral vector development services
- Growing number of public-private partnerships for viral vector development research
- Increasing investment in life sciences sector
Scope Of The Report
Report Attributes
Report Details
Report Title
Viral Vector Development Service Market Research Report
By Type
Retroviral Vectors, Lentiviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors, Others Viral Vectors
By Application
Pharmaceutical Manufacturers, Biotechnology Companies, Research Institutes
By Companies
UJIFILM Diosynth Biotechnologies, Sanofi, Spark Therapeutics, UniQure, MassBiologics, FinVector, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
Global Viral Vector Development Service Market Report Segments:
The global Viral Vector Development Service market is segmented on the basis of:
Types
Retroviral Vectors, Lentiviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors, Others Viral Vectors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pharmaceutical Manufacturers, Biotechnology Companies, Research Institutes
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- UJIFILM Diosynth Biotechnologies
- Sanofi
- Spark Therapeutics
- UniQure
- MassBiologics
- FinVector
- Brammer Bio
- Cell and Gene Therapy Catapult
- Cobra Biologics
Highlights of The Viral Vector Development Service Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Retroviral Vectors
- Lentiviral Vectors
- Adenoviral Vectors
- Adeno-associated Viral Vectors
- Others Viral Vectors
- By Application:
- Pharmaceutical Manufacturers
- Biotechnology Companies
- Research Institutes
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Viral Vector Development Service Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Viral Vector Development Service is a business that provides services to help companies develop and commercialize new viral products. These products can include vaccines, treatments for diseases, or new ways to spread viruses.
Some of the major players in the viral vector development service market are UJIFILM Diosynth Biotechnologies, Sanofi, Spark Therapeutics, UniQure, MassBiologics, FinVector, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Viral Vector Development Service Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Viral Vector Development Service Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Viral Vector Development Service Market - Supply Chain
4.5. Global Viral Vector Development Service Market Forecast
4.5.1. Viral Vector Development Service Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Viral Vector Development Service Market Size (000 Units) and Y-o-Y Growth
4.5.3. Viral Vector Development Service Market Absolute $ Opportunity
5. Global Viral Vector Development Service Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Viral Vector Development Service Market Size and Volume Forecast by Type
5.3.1. Retroviral Vectors
5.3.2. Lentiviral Vectors
5.3.3. Adenoviral Vectors
5.3.4. Adeno-associated Viral Vectors
5.3.5. Others Viral Vectors
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Viral Vector Development Service Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Viral Vector Development Service Market Size and Volume Forecast by Application
6.3.1. Pharmaceutical Manufacturers
6.3.2. Biotechnology Companies
6.3.3. Research Institutes
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Viral Vector Development Service Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Viral Vector Development Service Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Viral Vector Development Service Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Viral Vector Development Service Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Viral Vector Development Service Demand Share Forecast, 2019-2026
9. North America Viral Vector Development Service Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Viral Vector Development Service Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Viral Vector Development Service Market Size and Volume Forecast by Application
9.4.1. Pharmaceutical Manufacturers
9.4.2. Biotechnology Companies
9.4.3. Research Institutes
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Viral Vector Development Service Market Size and Volume Forecast by Type
9.7.1. Retroviral Vectors
9.7.2. Lentiviral Vectors
9.7.3. Adenoviral Vectors
9.7.4. Adeno-associated Viral Vectors
9.7.5. Others Viral Vectors
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Viral Vector Development Service Demand Share Forecast, 2019-2026
10. Latin America Viral Vector Development Service Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Viral Vector Development Service Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Viral Vector Development Service Market Size and Volume Forecast by Application
10.4.1. Pharmaceutical Manufacturers
10.4.2. Biotechnology Companies
10.4.3. Research Institutes
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Viral Vector Development Service Market Size and Volume Forecast by Type
10.7.1. Retroviral Vectors
10.7.2. Lentiviral Vectors
10.7.3. Adenoviral Vectors
10.7.4. Adeno-associated Viral Vectors
10.7.5. Others Viral Vectors
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Viral Vector Development Service Demand Share Forecast, 2019-2026
11. Europe Viral Vector Development Service Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Viral Vector Development Service Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Viral Vector Development Service Market Size and Volume Forecast by Application
11.4.1. Pharmaceutical Manufacturers
11.4.2. Biotechnology Companies
11.4.3. Research Institutes
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Viral Vector Development Service Market Size and Volume Forecast by Type
11.7.1. Retroviral Vectors
11.7.2. Lntiviral Vectors
11.7.3. Adenoviral Vectors
11.7.4. Adeno-associated Viral Vectors
11.7.5. Others Viral Vectors
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Viral Vector Development Service Demand Share, 2019-2026
12. Asia Pacific Viral Vector Development Service Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Viral Vector Development Service Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Viral Vector Development Service Market Size and Volume Forecast by Application
12.4.1. Pharmaceutical Manufacturers
12.4.2. Biotechnology Companies
12.4.3. Research Institutes
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Viral Vector Development Service Market Size and Volume Forecast by Type
12.7.1. Retroviral Vectors
12.7.2. Lentiviral Vectors
12.7.3. Adenoviral Vectors
12.7.4. Adeno-associated Viral Vectors
12.7.5. Others Viral Vectors
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Viral Vector Development Service Demand Share, 2019-2026
13. Middle East & Africa Viral Vector Development Service Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Viral Vector Development Service Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Viral Vector Development Service Market Size and Volume Forecast by Application
13.4.1. Pharmaceutical Manufacturers
13.4.2. Biotechnology Companies
13.4.3. Research Institutes
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Viral Vector Development Service Market Size and Volume Forecast by Type
13.7.1. Retroviral Vectors
13.7.2. Lentiviral Vectors
13.7.3. Adenoviral Vectors
13.7.4. Adeno-associated Viral Vectors
13.7.5. Others Viral Vectors
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Viral Vector Development Service Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Viral Vector Development Service Market: Market Share Analysis
14.2. Viral Vector Development Service Distributors and Customers
14.3. Viral Vector Development Service Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. UJIFILM Diosynth Biotechnologies
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Sanofi
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Spark Therapeutics
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. UniQure
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. MassBiologics
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. FinVector
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Brammer Bio
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Cell and Gene Therapy Catapult
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Cobra Biologics
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook